News Headlines Article

Merck Cholesterol Trial Can Continue
New York Times

Merck & Company said on Tuesday that an independent monitoring board would let it continue with a large clinical trial assessing the safety and effectiveness of its Vytorin cholesterol treatment. The panel’s decision suggested that no safety concerns had arisen for Vytorin.

The study, called Improve-It, will continue to its conclusion in September 2014, the drug maker said. The study is looking at whether Vytorin, with annual sales total $1.75 billion, can significantly reduce heart attacks, strokes and heart-related deaths compared with Merck’s older, generically available Zocor.